Search
Selected Filters
Filter Results
Displaying 21–30 of 268 research results
-
Aug 5, 2023
IZERVAY Approved by FDA for Treatment of Geographic Atrophy Secondary to Advanced Dry AMD
In two Phase 3 clinical trials, IZERVAY slowed the growth rate of lesions, the regions of cell loss in the central retina, associated with geographic atrophy (GA)
-
Jul 28, 2023
Belite Bio Doses First Patient in Phase 3 Clinical Trial for Advanced Dry AMD (GA) Therapy
The company’s emerging, oral treatment is designed to slow vision loss
-
Jul 12, 2023
PYC Doses First Patient in Clinical Trial of RNA Therapy for RP11 (PRPF31 Mutations)
The emerging RNA therapy is designed to boost expression of the PRPF31 protein
-
Jun 29, 2023
The five-year grant will advance the emerging treatments toward clinical trials
-
Jun 12, 2023
Beacon Therapeutics to Advance XLRP, Cone-Rod Dystrophy, and Dry AMD Gene Therapies
An emerging XLRP gene therapy acquired from AGTC is the company’s lead clinical program
-
Jun 1, 2023
Coave Reports Encouraging Phase 1/2 Clinical Trial Results for PDE6B Gene Therapy
The company is expanding the trial to enroll younger patients with less advanced disease
-
May 23, 2023
Summary of the Eighth Annual Retinal Cell & Gene Therapy Innovation Summit 2023
The Retinal Cell and Gene Therapy Innovation Summit has emerged as one of the most essential events for researchers and companies developing treatments and cures for retinal degenerative diseases. In its eighth year, the Innovation Summit featured 30 presentations from retina experts from around the world with more than 300 people in attendance.
-
May 2, 2023
Atsena Receives FDA Authorization to Launch a Gene Therapy Clinical Trial for XLRS
Known as The Lighthouse Study, the Phase ½ trial is expected to begin in mid-2023
-
May 1, 2023
Eric Pierce Receives Proctor Medal for Outstanding Achievements in Retinal Research
During his Proctor Award Lecture, Dr. Pierce reviewed encouraging clinical trial results for Editas’ CRISPR/Cas9 treatment for people with LCA10
-
Apr 28, 2023
Dr. Tucker is leading the development of GMP facilities for manufacturing clinical grade retinal therapies